Yes on Prop. 61:
DRUG PRICE PROTEST @ USC SCHOOL of PHARMACY
targeting Randall Vanderveen, PhD, R.Ph., the school’s former
Dean and current professor and advisor to the Leonard Schaeffer Center
for Health Policy & Economics at USC, and Mylan, Inc.’s ‘Six
Million Dollar Man,’ who reaped at least—$5.6 million in just one
stock transaction while serving on Mylan’s Board.
NOTE: This L.A. protest takes place on the same day and time that Mylan CEO Heather Bresch testifies in D.C. before the U.S. House Committee on Oversight and Government Reform—Sept. 21 [2pm ET].
WED. Sept. 21, 2016 at 10:30am-11:30am PT
USC School of Pharmacy, 1985 Zonal Ave., Los Angeles CA 90089
|Protesters including drug pricing advocates, ‘Yeson61’ ballot backers|
NEWS DESKS—For possible B-ROLL for your national EpiPen/Congressional Testimony news coverage -- 25+ protesters, “On the Road for Lower Drug Prices” tour bus, protesters call for USC Pharmacy Dean to step down
CONTACT: Ged Kenslea, AHF (323) 791-5526 email@example.com
Drug price advocates and people outraged over the price of Mylan, Inc.’s lifesaving EpiPen and other lifesaving drugs, including supporters of Proposition 61, the California Drug Price Relief Act, will mount a protest at the USC School of Pharmacy (1985 Zonal Ave., Los Angeles CA 90089) Wednesday, September 21, from 10:30am-11:30am(PT) targeting Randall Vanderveen, PhD, R.Ph., the school’s former Dean and current professor and advisor to the Leonard Schaeffer Center for Health Policy & Economics at USC—and an extremely well-compensated member of Mylan’s Board of Directors. Advocates will also protest USC, whose reputation has been damaged by news of Vanderveen's multi-million-dollar profiteering from serving on Mylan’s Board.
The L.A. protest will take place on the same day and during some of the time that Mylan CEO Heather Bresch testifies before the U.S. House Committee on Oversight and Government Reform (Sept. 21, 2pm ET] in Washington, DC, on the pricing and policies regarding the company’s lifesaving EpiPen, the price of which has risen 500% over the past decade. According to Bloomberg News, “CEO Heather Bresch is scheduled to appear before the U.S. House Committee on Oversight and Government Reform on Sept. 21, when members will question her about how the company raised the price of the life-saving injection to $600 for a two-pack, from $57 a shot when it took over sales of the product in 2007.”
Regarding Dr. Vanderveen’s drug company profiteering, a chart published in a Seeking Alpha article from February 10, 2015 (“Mylan Insiders Sell $118.4 Million In Stock To Avoid Transaction-Related Excise Tax”), revealed that Randall Vanderveen sold 106,551 shares of Mylan stock for $5,647,203—representing 297% of his pre-options exercise holdings1 sold.
In a biting opinion piece by David Martin, Founder of M-Cam2, published on CNBC on August 25, 2016, “Media outlets should be doing their stories on … members of Mylan's board of directors, who were willing to endorse a business strategy as ethical as arms dealers in Lord of War.”
Today, EpiPens sell for $608 for a package of two. In his online CNBC commentary, Martin noted, “In 2011, the same product sold for $164. In 2007, it was available for $57.” He ended his piece writing, “… we should demand accountability where it's really due – the Patent Office that granted an unjustified and unpatentable monopoly, the FDA which props up the illusion, and a board of directors at Mylan who don't take the time to inform themselves of their own company's misdeeds.”
“Academic institutions like USC lend powerful credibility to operators like Mylan by letting institutional leaders like Dr. Vanderveen serve—and profit—on the boards of such ethically-challenged companies,” said Donna Stidham, RN, a mother, nurse for 43 years and AHF’s Chief of Managed Care. “USC and others should realize the reputational damage their institutions suffer by letting their leaders and professors get in bed with the Mylans of the world and work diligently to put a stop to it.”
Background on Prop 61
Proposition 61 would require the state of California to negotiate with drug companies for drug prices that are no more than is paid for the same drugs by the U.S. Department of Veterans Affairs (DVA). Unlike Medicare, the DVA negotiates for drug prices on behalf of the millions veterans it serves, and pays on average 20-24 percent less for medications than other government agencies, and up to 40 percent less than Medicare Part D.
Prop 61 Endorsements
Prop. 61 has been endorsed by AARP California, the California Nurses Association, U.S. Sen. Bernie Sanders and his organization Our Revolution, former U.S. Secretary of Labor Robert Reich, civil rights and labor activist Dolores Huerta, Rev. Al Sharpton, the Urban League, AIDS Healthcare Foundation, Campaign for a Healthy California, Progressive Democrats of America, Social Security Works, and the Vote Vets Action Fund. A full list of endorsements can be found at: http://www.yeson61.com/endorsements
Paid for by Yes on Prop 61, Californians for Lower Drug Prices, With Major Funding by AIDS Healthcare Foundation and California Nurses Association PAC. FPPC ID#1376791
1 Many of the sales made were done by way of Code M (exercise of conversion of derivative security) so the total shares sold after being converted from options often exceeds the total amount of shares owned prior to options conversion for the insider. This means that the MYL director or insider dumped options immediately upon conversion as included in the plans described by the company in the 14A.
2 M-CAM is a global financial institution that advises corporations and investors on corporate finance and asset allocation by underwriting intellectual property (IP) and intangible assets (IA).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920006997/en/Business Wire
Last updated on: 21/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.